Status:
TERMINATED
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Lead Sponsor:
Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-88 years
Phase:
PHASE3
Brief Summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each pa...
Eligibility Criteria
Inclusion
- Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
- Caregiver will participate and be able to attend clinic visits with patient.
Exclusion
- Significant neurological disease other than AD, or a major psychiatric disorder
- Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
- Woman of childbearing potential
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT00676143
Start Date
January 1 2008
End Date
November 1 2012
Last Update
June 10 2016
Active Locations (288)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Psychiatric Medicine
Birmingham, Alabama, United States, 35294
2
Participant and Clinical Interactions Resources
Birmingham, Alabama, United States, 35294
3
UAB Clinical Research Pharmacy-Russell Clinic
Birmingham, Alabama, United States, 35294
4
University of Alabama-Birmingham
Birmingham, Alabama, United States, 35294